LDS/Medical Tests/LiquidHALLMARK Multi Cancer Panel

LiquidHALLMARK Multi Cancer Panel

The LiquidHALLMARK™ Multi-Cancer Panel is a comprehensive next-generation sequencing (NGS)-based liquid biopsy assay designed to non-invasively profile the molecular landscape of solid tumors using circulating tumor DNA (ctDNA) and RNA (ctRNA) extracted from plasma. Unlike most liquid biopsies that analyze only DNA, LiquidHALLMARK uniquely includes cfRNA analysis, enhancing fusion detection and transcript-level alterations.

The panel interrogates over 80 clinically relevant cancer-related genes for somatic alterations such as single nucleotide variants (SNVs), insertions and deletions (indels), copy number alterations (CNAs), gene fusions, and microsatellite instability (MSI). Additionally, the assay includes screening for oncogenic viruses like Epstein-Barr Virus (EBV) and Hepatitis B Virus (HBV), relevant in virus-associated malignancies. This comprehensive profiling supports precision oncology by guiding therapeutic selection particularly for targeted therapies and immunotherapies monitoring treatment response and detecting minimal residual disease or recurrence.

  • Stratification of patients for targeted therapy, chemotherapy, and immunotherapy
  • Identification of actionable mutations across multiple cancer types
  • Viral oncogene screening to inform etiology and therapeutic approach
  • Suitable alternative to tissue biopsy in cases with inaccessible tumors or insufficient tissue

A detailed report lists detected genomic alterations across 80+ genes with corresponding clinical interpretations, potential therapeutic targets, FDA-approved therapies, investigational drugs, and clinical trial eligibility.

Not applicable; interpretation is based on detected genomic alterations and their known clinical significance

Ultra-deep NGS utilizing proprietary AmpliMARK™ technology from Lucence. Sequencing includes both ctDNA and ctRNA for comprehensive variant detection.

Whole blood (EDTA tubes).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
Tissue biopsy with immunohistochemistry or DNA/RNA panel (if needed), Serum tumor markers (e.g., CEA, CA 19-9, AFP), PD-L1 testing or TMB (tumor mutational burden) for immunotherapy decision-making.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login